Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients

Christoph Zenzmaier1*, Martin Heitz1, Helmut Klocker2, Marion Buck3, Robert A Gardiner3 and Peter Berger1*

Abstract

Background: Expression of Dkk-3, a secreted putative tumor suppressor, is altered in age-related proliferative disorders of the human prostate. We now investigated the suitability of Dkk-3 as a diagnostic biomarker for prostate cancer (PCa) in seminal plasma (SP).

Methods: SP samples were obtained from 81 patients prior to TRUS-guided prostate biopsies on the basis of elevated serum prostate-specific antigen (PSA; > 4 ng/mL) levels and/or abnormal digital rectal examination. A sensitive indirect immunoenzymometric assay for Dkk-3 was developed and characterized in detail. SP Dkk-3 and PSA levels were determined and normalized to total SP protein. The diagnostic accuracies of single markers including serum PSA and multivariate models to discriminate patients with positive (N = 40) and negative (N = 41) biopsy findings were investigated.

Results: Biopsy-confirmed PCa showed significantly higher SP Dkk-3 levels (100.9 ± 12.3 vs. 69.2 ± 9.4 fmol/mg; p = 0.026). Diagnostic accuracy (AUC) of SP Dkk-3 levels (0.633) was enhanced in multivariate models by including serum PSA (model A; AUC 0.658) or both, serum and SP PSA levels (model B; AUC 0.710). In a subpopulation with clinical follow-up > 3 years post-biopsy to ensure veracity of negative biopsy status (positive biopsy N = 21; negative biopsy N = 25) AUCs for SP Dkk-3, model A and B increased to 0.667, 0.724 and 0.777, respectively.

Conclusions: In multivariate models to detect PCa, inclusion of SP Dkk-3 levels, which were significantly elevated in biopsy-confirmed PCa patients, improved the diagnostic performance compared with serum PSA only.

Keywords: Dickkopf-3, Dkk-3, IEMA, prostate-specific antigen, seminal fluid

Background

The secreted glycoprotein Dickkopf-related protein 3 (Dkk-3) is the most divergent member of the human Dickkopf family [1,2] that, in contrast to other family members, does not modulate Wnt signaling [3,4]. Dkk-3 has been proposed to represent a novel tumor suppressor since gene expression is downregulated in various tumor cells [5-9] and hypermethylation of its promoter correlates with cancer occurrence [10,11].

Our previous results indicated a possible link between Dkk-3 expression and age-associated processes in the human prostate. Serial analysis of gene expression (SAGE) of human prostate basal epithelial cells revealed specific induction of DKK3 gene during cellular senescence in vitro [12]. Moreover, Dkk-3 was found downregulated in vivo in prostate epithelium of patients suffering from the age-related prostatic conditions benign prostatic hyperplasia (BPH) and prostate cancer (PCa), with this downregulation counterbalanced by increased Dkk-3 protein expression in the endothelial cells of the tumor neovasculature [13].

This study was intended to assess changes in Dkk-3 content in prostatic fluid in these two conditions and its potential as a diagnostic marker for PCa. Since prostatic secretions constitute approximately 30% of seminal fluid volume [14], of all readily obtainable body fluids, ejaculate supernatant (seminal plasma; SP) reflects the contemporary status of the prostate best. We previously demonstrated that Dkk-3 could be detected in SP in apparently healthy donors at concentrations of 2.59 ± 0.41 nmol/L (range 1.62-5.25 nmol/L) that was higher that plasma Dkk-3 levels (1.22 ± 0.04 nmol/L) but much
less than Dkk-3 levels found in cerebrospinal fluid (28.2 ± 1.3 nmol/L) [15]. SP Dkk-3 and SP prostate-specific antigen (PSA) levels were analyzed from 81 patients who underwent transrectal ultrasound (TRUS)-guided prostate biopsies due to elevated serum PSA levels and/or abnormal digital rectal examination (DRE). Ejaculate specimens were obtained prior to biopsy. SP Dkk-3 and SP PSA levels were compared, alone and in combination with serum PSA, to the diagnostic performance of serum PSA alone to detect PCa in univariate and multivariate models.

Methods
Subjects - SP samples
Eighty-one patients who were to undergo TRUS-guided biopsies because they had an abnormal serum PSA level (> 4 ng/mL) and/or abnormal DRE were recruited into the study from the outpatient department or from private rooms of urologists at Royal Brisbane and Women’s Hospital (RBWH) between 1996 and 2009. Of this group, 40 men were confirmed to have cancer and 41 men had negative biopsies. Subsequently, patients with negative TRUS biopsy findings were followed with PSA and DREs and with further TRUS biopsies as indicated in selected cases to ensure the veracity of the TRUS-negative findings. A subgroup of 25 patients with negative and 21 with positive biopsy had a clinical follow-up of > 3 years (collected between 1996 and 08/2007). This subset of patients had been selected from our archive because we were as sure as we can be that those designated not to have prostate cancer were true negatives. All SP specimens were obtained before biopsy and treatment and after giving informed consent. Patients collected ejaculate via masturbation into urine collection jars containing 20 mL of Hanks balanced salt solution in the morning at home and brought them to the hospital within 2 hours of collection (without freezing or cooling, i.e. at temperatures from ~5-25°C) where they were processed within 15 minutes after arrival. Samples were layered over 10 mL of 64% isotonic Percoll (Amersham Biosciences) and centrifuged at 2200 rpm for 30 min at 4°C. The ejaculate supernatants (SP) were layered over 10 mL of 64% isotonic Percoll (Amer- sham Biosciences) and centrifuged at 2200 rpm for 30 min at 4°C. The ejaculate supernatants (SP) were removed, aliquoted and stored at -70°C until further processing (as reported previously [16,17]). The study had the approval of the ethics committees of the RBWH and University of Queensland.

Establishment of a sensitive Dkk-3 assay
A series of six monoclonal Antibodies (mAb) INN (bruck)-Dkk3-1 to INN-Dkk3-6 as previously described [18] and an affinity purified polyclonal goat anti Dkk-3 antibody (R&D Systems Cat.#AF1118) were characterized by radioimmunoassays (RIA) according to affinity, molecular epitope localization and specificity with native (untagged) Dkk-3 and the commercially available homologous proteins Dkk-1, Dkk-4 and Sgy-1 (R&D Systems) as described elsewhere [18]. The antibodies with the highest affinity towards Dkk-3 (mAb INN-Dkk3-1 and the goat polyclonal antibody) showed no significant reactions towards the homologous proteins Dkk-1 and Dkk-4 however the polyclonal antibody when tested at a concentration of 5 μg/mL reacted slightly with the homologous protein Sgy-1 (Figure 1A). In competitive RIA to assess cross-reactivity increasing concentrations of Dkk-3 or Sgy-1 competed with 125I labeled Dkk-3 (approximately 25,000 cpm) for binding to 30 ng of polyclonal goat anti Dkk-3 antibody in 300 μL total reaction volume (1% BSA/PBS) overnight at 4°C. Separation of bound from free tracer was performed as described [18], and cross-reactivity towards Sgy-1 was determined to be 0.025% (Figure 1B). Epitope mapping by polypeptide screening revealed localization of the INN-Dkk3-1 epitope in the N-terminal region (amino acids 21-147) while the polyclonal antibody predominantly reacted with the C-terminal region (amino acids 200-350; data not shown).

A sensitive sandwich immunoradiometric assay (IRMA) was established with mAb INN-Dkk3-1 (coating antibody) and the 125I labeled goat polyclonal antibody (R&D Systems) as described previously [19]. All samples were run in duplicate and results calculated from specific mean signal (mean - zero standard). Native i.e. untagged Dkk-3 purified via HPLC (anion exchange followed by size exclusion chromatography) from conditioned media of stably transfected LNCaP cells [13] was used as standard. Cross-reactivity was shown to be < 0.1% for Sgy-1 and < 0.01% for Dkk-1 and Dkk-4 (Figure 1C).

To increase sensitivity and to allow higher sample throughput, the assay was commuted to a 96-well plate based indirect immunoenzymometric assay (IEMA) described previously [18] by replacement of the 125I-labeled antibody by a biotinylated variant of the polyclonal goat anti Dkk-3 antibody (R&D Systems Cat. #BAF1118). All samples were run in duplicate and results were calculated from specific mean signal (mean - zero standard). Recovery was 92% and sensitivity 1 pmol/L. The intra- and inter-assay variances (%CV) at a protein concentration of 40 pmol/L were 11% and 13%, respectively.

PSA and total protein measurements
Serum PSA was assayed using a fluoroimmunoenzymometric two-site assay (Medics 1200 Dx AIA, Tosoh Corp.). SP PSA values were analyzed by the ADVIA Centaur PSA assay (Siemens Healthcare Diagnostics) at a dilution of 1:5000. SP Dkk-3 and PSA levels were normalized to total protein levels determined by the Pierce BCA Protein Assay Kit (Thermo Scientific).
Figure 1 Establishment of the Dkk-3 assay. mAb INN-Dkk3-1 and goat polyclonal antibody (R&D Systems) showed no significant cross-reactivities with homologous proteins Dkk-1 and Dkk-4. The polyclonal antibody (5 μg/mL) showed weak reactivity for the homologous protein Sgy-1 in a direct binding RIA (A). In a competitive RIA the goat polyclonal antibody showed a cross-reactivity (XR) of 0.025% for Sgy-1 (B). A standard curve from 0.25 pmol/L - 250 pmol/L Dkk-3 in comparison to the homologous proteins at a concentration of 1000 pmol/L revealed cross-reactivities in the sandwich assay of < 0.01% (C). The established sandwich assay had a recovery of 92% and sensitivity of 1 pmol/L. The intra- and inter-assay variances (%CV) at a protein concentration of 40 pmol/L were 11% and 13%, respectively.
Statistical analyses

Assay sensitivity was defined as the mean signal of non-specific binding (NSB = zero standard) plus three standard deviations (NSB + 3SD). Percent coefficient of variation (%CV) was used as a measure of dispersion about the mean and expressed SD as a percentage of the mean.

Statistical differences among groups were calculated by Mann-Whitney test. Multivariate logistic regression was used to analyze correlations between investigated markers and PCa diagnostic status and the quality of the obtained models were estimated by Hosmer-Lemeshow goodness-of-fit tests. The diagnostic performance of the tested variables and the multivariate models was evaluated by plotting the receiver-operating characteristics (ROC) curve and calculating the area under the ROC curve (AUC). Associations between the investigated markers, age at time of the ejaculation specimen and Gleason score were evaluated using Pearson correlation analysis or Spearman’s rank correlation analysis when data belonged to categorial variables.

All statistical analyses were performed using PASW Statistics 18 (IBM).

Results

The characteristics of all 81 patients and the 46 patients with a follow-up of > 3 years are summarized in Table 1. Serum PSA as well as SP Dkk-3 levels (characteristics of the sandwich assay depicted in Figure 1) were found significantly higher in the PCa confirmed patients in both, the all patients cohort as well as the > 3 year follow-up subgroup. SP PSA levels were although also slightly elevated not significantly different. A multivariate logistic regression model based on serum PSA and SP Dkk-3 levels (model A) significantly discriminated negative from positive biopsies in both cohorts (Table 2; all patients: \( p = 0.007 \), predictive accuracy = 64.2%; follow-up > 3 years: \( p = 0.007 \), predictive accuracy = 73.9). Although not significantly different between patients with positive and negative biopsies, inclusion of SP PSA (model B) increased the predictive accuracy of the model for the cohort of all patients.

The diagnostic performances of the univariate test variables and the multivariate models were determined by ROC analyses (Figure 2 and Table 3). AUCs, as a measure for diagnostic accuracy, for serum PSA, SP Dkk-3, SP PSA, model A and model B were 0.644, 0.633, 0.565, 0.658 and 0.710 in the cohort of all patients and 0.696, 0.667, 0.562, 0.724 and 0.777 in patients with > 3 years clinical follow-up, respectively, showing that the multiplex models had higher AUCs in both cohorts compared with the single markers and model B higher accuracy compared with model A.

Moreover, except for SP PSA all AUCs where higher in the > 3 year follow-up cohort.

Lastly, correlations between the individual markers, age and biopsy Gleason score were analyzed (Table 4). SP Dkk-3 and SP PSA were found independent for serum PSA, Age and Gleason score whereas serum PSA levels correlated with Gleason score (all patients: \( p = 0.034 \); > 3 years follow-up: \( p = 0.024 \)) but not with age. Interestingly SP Dkk-3 levels correlated with SP PSA levels (all patients: \( p = 0.013 \) but this correlation was

### Table 1 Characteristics of the study cohort.

| Characteristic | Negative biopsy | Positive biopsy | \( p \) value |
|----------------|-----------------|----------------|------------|
| Patients, N    | 41              | 40             |            |
| Age*, yr       | Mean ± SEM      | 61.0 ± 1.3     | 61.5 ± 1.3 |
|                | Median (IQR)    | 62.5 (57.1 - 67.0) | 61.9 (55.6 - 66.6) |
| serum PSA [ng/mL] | Mean ± SEM | 7.5 ± 1.0 | 11.6 ± 1.9 |
|                | Median (IQR)    | 6.2 (4.1 - 8.9) | 7.3 (5.8 - 13.3) |
| SP Dkk-3 [fmol/mg]** | Mean ± SEM | 69.2 ± 9.4 | 100.9 ± 12.3 |
|                | Median (IQR)    | 55.7 (35.8 - 91.2) | 74.5 (41.7 - 124.5) |
| SP PSA [μg/mg]** | Mean ± SEM      | 23.8 ± 3.3     | 28.0 ± 3.5 |
|                | Median (IQR)    | 16.8 (8.1 - 35.9) | 19.9 (10.8 - 42.5) |
| Biopsy Gleason score ≤ 6 | 6 |
|                | 7               | 26             |
| ≥ 8            | 8               |               |

Clinical follow-up > 3 yr

| Characteristic | Negative biopsy | Positive biopsy | \( p \) value |
|----------------|-----------------|----------------|------------|
| Patients, N    | 25              | 21             |            |
| Age*, yr       | Mean ± SEM      | 63.1 ± 1.6     | 61.6 ± 23 |
|                | Median (IQR)    | 64.0 (60.9 - 68.9) | 60.5 (53.7 - 69.8) |
| serum PSA [ng/mL] | Mean ± SEM | 8.0 ± 1.6 | 143 ± 3.3 |
|                | Median (IQR)    | 6.2 (3.6 - 10.4) | 9.2 (6.5 - 16.0) |
| SP Dkk-3 [fmol/mg]** | Mean ± SEM | 56.3 ± 8.4 | 1000 ± 16.6 |
|                | Median (IQR)    | 49.6 (22.3 - 76.4) | 763 (35.9 - 169.4) |
| SP PSA [μg/mg]** | Mean ± SEM      | 23.4 ± 4.5     | 274 ± 5.1 |
|                | Median (IQR)    | 16.8 (7.3 - 40.1) | 195 (12.7 - 35.0) |
| Biopsy Gleason score ≤ 6 | 3 |
|                | 7               | 14             |
| ≥ 8            | 4               |               |

SEM, standard error of the mean; IQR, interquartile range; PSA, prostate-specific antigen; SP, seminal plasma; * at time of ejaculate specimen; ** per total protein; \( p \) values determined by Mann-Whitney test.
limited to patients with biopsy confirmed PCa (all patients: \( p = 0.007 \); > 3 years follow-up: \( p = 0.026 \)) while no correlation was observed in patients with negative biopsies (all patients: \( p = 0.301 \); > 3 years follow-up: \( p = 0.620 \)).

**Discussion**

Serum PSA is currently the most widely used PCA screening test, however, PSA is organ- but not disease-specific, thus its value to predict PCa is limited and there is a need for additional disease markers. We consider SP as an ideal source to monitor pathological changes in the prostate since it more directly reflects local glandular production than other sources such as peripheral blood. Moreover, SP donation is completely non-invasive avoiding the discomfort and possible concerns associated with prostate massage necessary to obtain post-massage urine. Previously, we reported that the inactive free:total PSA ratios in SP from men with suspected PCa did not distinguish between those harboring malignant as opposed to benign disease [16]. The present study was designed to assess changes in Dkk-3

### Table 2 Multivariate logistic regression analyses to assess the predictive value in prostate cancer detection.

| Cohort                   | Variable     | \( \beta \)-coefficient | OR          | 95% CI               | \( p \)-value | Predictive accuracy % | H-L \( p \)-value |
|--------------------------|--------------|--------------------------|-------------|----------------------|--------------|------------------------|------------------|
| all patients             | model A      |                          |             |                      |              |                        |                  |
|                          | serum PSA    | 0.071                    | 1.074       | 0.997 - 1.157        | 0.06         |                        |                  |
|                          | SP Dkk-3     | 0.008                    | 1.008       | 1.000 - 1.016        | 0.039        |                        |                  |
|                          | model B      |                          |             |                      |              |                        |                  |
|                          | serum PSA    | 0.07                    | 1.072       | 0.996 - 1.002        | 0.063        |                        |                  |
|                          | SP Dkk-3     | 0.01                    | 1.010       | 1.002 - 1.018        | 0.019        |                        |                  |
|                          | SP PSA       | 0.017                   | 1.018       | 0.995 - 1.041        | 0.13         |                        |                  |
| clinical follow-up > 3 yr| model A      |                          |             |                      |              |                        |                  |
|                          | serum PSA    | 0.071                   | 1.074       | 0.992 - 1.164        | 0.08         |                        |                  |
|                          | SP Dkk-3     | 0.014                   | 1.015       | 1.002 - 1.027        | 0.02         |                        |                  |
|                          | model B      |                          |             |                      |              |                        |                  |
|                          | serum PSA    | 0.069                   | 1.072       | 0.991 - 1.159        | 0.083        |                        |                  |
|                          | SP Dkk-3     | 0.016                   | 1.016       | 1.004 - 1.029        | 0.012        |                        |                  |
|                          | SP PSA       | 0.018                   | 1.018       | 0.988 - 1.049        | 0.238        |                        |                  |

OR, odds ratio; CI, confidence interval; H-L, Hosmer-Lemeshow test; PSA, prostate-specific antigen; SP, seminal plasma.

**Figure 2** Receiver operator characteristics (ROC) curves. ROC curves of serum prostate-specific antigen (PSA), seminal plasma (SP) Dkk-3 and SP PSA levels and the multivariate models based on serum PSA and SP Dkk-3 (model A) or on all three individual markers (model B) for (A) the entire cohort and (B) patients with > 3 years clinical follow-up.
levels in SP and its potential for discriminating benign from malignant prostatic conditions in patients who were to undergo TRUS-guided biopsy due to elevated serum PSA (> 4 ng/mL) and/or abnormal DRE.

With the IEMA developed in our laboratory, SP Dkk-3 levels were found significantly higher in patients with biopsy confirmed PCa (100.9 ± 12.3 vs. 69.2 ± 9.4 fmol/mg). Of note, this difference was more pronounced in the subgroup of patients with a clinical follow-up of > 3 years (100.0 ± 16.6 vs. 56.3 ± 8.4 fmol/mg) for whom, as a consequence, there was greater veracity for the negative biopsy finding to be correct (Table 1).

While Dkk-3 levels as a single marker distinguished between prostate cancer and non-cancer on the basis of TRUS biopsies in the study cohort with a similar diagnostic accuracy compared with serum PSA (SP Dkk-3: AUC = 0.633; serum PSA: AUC = 0.644), the diagnostic accuracy of SP Dkk-3 levels was enhanced in multivariate models including serum PSA (model A) and both, serum and SP PSA levels (model B). Neither SP Dkk-3 nor SP PSA levels correlated with biopsy Gleason scores. However, this might be in part due to the patient cohort characteristics with approximately 2/3 of all positive biopsies reported as Gleason 7 (either Gleason 3+4 or Gleason 4+3). Of interest SP Dkk-3 negatively correlated with SP PSA levels in the positive biopsy cohorts, which might be responsible for the higher accuracy of model B compared with model A.

The biological significance of the increase in SP Dkk-3 levels in patients with positive vs. negative PCa biopsy findings remains unclear. As expression of Dkk-3 in secretory epithelial cells of the prostate is reduced in both PCa [5,13,20] and BPH [13], one might have expected a similar effect on SP Dkk-3 levels in patients with both these conditions. However, it is conceivable that the elevated Dkk-3 levels in PCa SP are derived from the tumor neovascularature, where high levels of Dkk-3 are produced [13]. Elevated serum PSA levels in PCa patients are supposed to be primarily an effect of tissue degradation and thus increased tissue permeability while in normal/BPH tissue an intact basement membrane prevents leakage [21]. Likewise, Dkk-3 as a secreted protein of similar size (PSA protein backbone: 237 aminoacids; Dkk-3 protein backbone: 329 aminoacids) might be able to diffuse through the disorganized PCa tissue.

Due to the limited number of SP samples available, especially from patients with long-term follow-up, it was not useful to further stratify the biopsy confirmed PCa patients according to their risk in order to more closely investigate the SP Dkk-3 and SP PSA correlation within this cohort.

Given the limited diagnostic accuracy of single markers including PSA, much effort has been made to

| Table 3 Determination of diagnostic accuracy. |
|---------------------------------------------|
|                | all patients | clinical follow-up > 3 yr |
|                |        |                          | AUC | 95% CI |        |
| serum PSA      | 0.644 | 0.524 - 0.763 | 0.696 | 0.544 - 0.848 |
| SP Dkk-3       | 0.633 | 0.512 - 0.754 | 0.667 | 0.509 - 0.825 |
| SP PSA         | 0.565 | 0.439 - 0.690 | 0.562 | 0.394 - 0.730 |
| model A        | 0.658 | 0.539 - 0.776 | 0.724 | 0.568 - 0.880 |
| model B        | 0.710 | 0.597 - 0.824 | 0.777 | 0.638 - 0.917 |

Areas under the receiver operator characteristics curve for univariate test variables and multivariate models.

| Table 4 Correlative associations between univariate test variables. |
|---------------------------------------------------------------|
|                      | SP PSA | serum PSA | Age | Gleason* |
|                      | all     | neg     | pos | all     | neg     | pos | all     | neg     | pos | r (p-value) | r (p-value) | r (p-value) | r (p-value) |
| all patients         |        |         |     |        |         |     |        |         |     | -0.276     | -0.165     | (0.013)     | (0.906)    |
|                      |         |         |     |        |         |     |        |         |     | (0.301)    | (0.007)    | (0.400)     | (0.183)    |
| SP Dkk-3             | 1       | 1       | 1   | 0.020  | 0.125   | -0.068 | -0.320 | -0.107  | 0.037  | (0.860)    | (0.437)    | (0.679)     | (0.777)    |
|                      |         |         |     | (0.860) | (0.437) | (0.679) | (0.777) | (0.507) | (0.822) | (0.483)    | (0.034)    | (0.034)     | (0.034)    |
| serum PSA            | 0.020   | 0.125   | -0.038 | 1       | 1       | 1     | 0.117  | -0.107  | 0.024  | 0.336      | 0.013      | 0.013       | 0.013      |
|                      |         |         |     | (0.860) | (0.437) | (0.679) | (0.777) | (0.507) | (0.884) | (0.034)    | (0.034)    | (0.034)     | (0.034)    |
| clinical follow-up   |        |         |     |        |         |     |        |         |     | -0.294     | -0.104     | (0.054)     | (0.123)    |
| > 3 yr               |        |         |     |        |         |     |        |         |     | (0.620)    | (0.026)    | (0.506)     | (0.111)    |
|                      |         |         |     |        |         |     |        |         |     | (0.506)    | (0.111)    | (0.450)     | (0.135)    |
|                      |         |         |     |        |         |     |        |         |     | (0.506)    | (0.111)    | (0.450)     | (0.135)    |
| SP PSA               | 1       | 1       | 1   | 0.043  | 0.219   | -0.099 | 0.099  | 0.071  | 0.169  | 0.123      | 0.013      | 0.013       | 0.013      |
|                      |         |         |     | (0.777) | (0.293) | (0.668) | (0.511) | (0.844) | (0.465) | (0.431)    | (0.034)    | (0.034)     | (0.034)    |
| serum PSA            | -0.100  | 0.219   | -0.099 | 1       | 1       | 1     | 0.085  | 0.312  | 0.018  | 0.491      | 0.013      | 0.013       | 0.013      |
|                      |         |         |     | (0.506) | (0.293) | (0.668) | (0.572) | (0.129) | (0.938) | (0.024)    | (0.024)    | (0.024)     | (0.024)    |

SP, seminal plasma; PSA, prostate-specific antigen; neg, negative biopsy; pos, positive biopsy; r, correlation coefficient.

Correlations were calculated by Pearson correlation analysis except for *Spearman’s rank correlation analysis.

Zenzmaier et al. *Journal of Translational Medicine* 2011, 9:193
http://www.translational-medicine.com/content/9/1/193
identify potential additional PCA markers from different sources including SP [22-24]. Our data demonstrate that SP is a valuable and valid source for biomarkers of prostate disease. The most promising attempt to improve PCA diagnosis appears the establishment of a set of individual biomarkers. Thus, SP Dkk-3 should be considered in a panel of markers such as prostate cancer antigen 3 (PCA3) and/or hepsin [25] to be evaluated in combination in future validation studies.

Conclusions
A newly established sensitive and specific IEMA for Dkk-3 revealed significantly higher SP Dkk-3 levels in men with biopsy confirmed PCa indicating its inclusion in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 8 August 2011 Accepted: 10 November 2011
Published: 10 November 2011

References
1. Krupnik VE, Sharp JD, Jiang C, Robson K, Chickering TW, Amaravadi L, Brown DE, Guyot D, May G, Leiby K, et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999; 238(2):301-313.
2. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006; 25(7):7469-7481.
3. Wu W, Glinka A, Delius H, Niehrs C. Mutual antagonism between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr Biol 2000; 10(24):1611-1614.
4. Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001; 411(6835):321-325.
5. Hsieh SY, Hsieh PS, Chiu CT, Chen YW. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 2004; 23(57):9183-9189.
6. Tsuji T, Miyazaki M, Sakaguchi M, Inoue Y, Namba M. A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. Biochem Biophys Res Commun 2000; 268(1):20-24.
7. Tsuji T, Nozaki I, Miyazaki M, Sakaguchi M, Pu H, Hamazaki Y, Iijima O, Namba M. Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. Biochem Biophys Res Commun 2001; 289(1):257-263.
8. Nozaki I, Tsuji T, Iijima O, Ohmura Y, Andou A, Miyazaki M, Shimizu N, Namba M. Reduced expression of REIC/Dkk-3 gene in non-small cell lung cancer. Int J Oncol 2001; 19(3):117-121.
9. Kurose K, Sakaguchi M, Nasu Y, Ebara S, Kaku H, Kariyama R, Araco Y, Miyazaki M, Tsuchiya T, Namba M, et al. Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. J Urol 2004; 171(3):1318-1318.
10. Kobayashi K, Ouchida M, Tsuji T, Hanafusa H, Miyazaki M, Namba M, Shimizu N, Shimizu K. Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene 2002; 282(1-2):151-158.
11. Lodigian D, Epanchintsev A, Menssen A, Diebold J, Hermerling H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65(10):4214-4227.
12. Untergasser G, Koch HB, Menssen A, Hermerling H. Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res 2002, 62(1):6255-6262.
13. Zenzmaier C, Untergasser G, Herrmann M, Dimhofer S, Sampson N, Berger P. Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue. Prostate 2008; 68(5):540-547.
14. Sampson N, Untergasser G, Plas E, Berger P. The ageing male reproductive tract. J Pathol 2007; 211(2):206-218.
15. Zenzmaier C, Marksteiner J, Kiefer A, Berger P, Humpel C. Dkk-3 is elevated in CSF and plasma of Alzheimer’s disease patients. J Neurochem 2009, 110(2):653-661.
16. Cincotta JA, Merritt T, Devoss K, Swanson C, Hamlyn L, Scells B, Rohde P, Lavin MF, Axley J, Gardiner RA. Inactive free: total prostate specific antigen ratios in ejaculate from men with suspected and known prostate cancer, compared with young control men. BJU Int 2000, 86(4):453-458.
17. Gardiner RA, Samarutanga ML, Gwynne RA, Clague A, Seymour GJ, Lavin MF. Abnormal prostatic cells in ejaculates from men with prostate cancer—a preliminary report. Br J Urol 1996, 78(3):414-418.
18. Zenzmaier C, Skiepoz L, Berger P. Increase of Dkk-3 blood plasma levels in the elderly. Exp Gerontol 2008, 43(9):867-870.
19. Berger P, Panmoung W, Kharchabi D, Mayregger B, Wick G. Antigenic features of human follicle stimulating hormone delineated by monoclonal antibodies and construction of an immunoradiometric assay. Endocrinology 1988, 123(5):2351-2359.
20. Kawano Y, Kitaoka M, Hamada Y, Walker MM, Waxman J, Kypta RM. Regulation of prostate cell growth and morphogenesis by Dickkopf-3. Oncogene 2006; 25(19):6526-6537.
21. Schalken JA. Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia. BJU Int 2004, 93(Suppl 1):S-9.
22. Clarke RA, Schira HJ, Catto JW, Lavin MF, Gardiner RA. Markers for detection of prostate cancer. Cancer 2010, 21:1125-1154.
23. Malcovat DC, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med 2009, 60:139-151.
24. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognostic of prostate cancer. Clin Chem 2008, 54(12):1951-1960.
25. Leaders RA, Burger MJ, Teyab MA, Purdie DM, Scells B, Samarutanga H, Lavin MF, Gardiner RA. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 2005, 114(6):950-956.